News

Switching from brand to generic eye drops for surgical prophylaxis following cataract surgery caused no difference in endophthalmitis rates and resulted in substantial cost savings in a single-center comparison.

: Highlights are presented from what is believed to be the first head-to-head comparison of one, two, and three stents inserted as a stand-alone procedure.

Findings from basic science research elucidating the mechanisms of retinal ganglion cell axon degeneration, regeneration, and death have identified new therapeutic targets for glaucoma that are being investigated in preclinical and clinical studies.

Capturing clinical images with the integration of electronic health records and smartphone applications can enhance practice efficiency and compliance.

The initial 36-month results are highlighted from a novel, soft and permanent, minimally invasive ab interno collagen implant used to optimize aqueous drainage to the subconjunctival space.

A potent and selective transforming growth factor (TGF)-β2 LNA-modified antisense oligonucleotide induces biologic responses consistent with the drug’s expected molecular mechanism of action in different preclinical ocular surface disease models.

A proprietary glaucoma device has changed current thinking about cyclophotocoagulation by offering another option in the glaucoma treatment algorithm and allowing earlier laser intervention when medical treatment comes up short.

Following specific steps in the retail-selling process will increase the likelihood that customers will make a purchase.

Active research in neuroprotection, neuroregeneration, and sustained drug delivery is expected to lead to better options for management of glaucoma.

Endoscopic cyclophotocoagulation with vitrectomy and pars plana treatment is effective in reducing IOP in patients with ultra-refractory glaucoma, reducing the need for medications and being relatively well tolerated by patients.

In this physician perspective, Robert J. Noecker, MD, MBA, describes the results he has experienced since he has begun applying an ocular sealant as the last step of every filtering procedure.

What would happen if all ophthalmic staff were allocated such a salary?

There has been growing concern within the medical industry that senior physicians can negatively impact patient care.

A new gene therapy could preserve vision in people with retinitis pigmentosa and might effectively treat other degenerative nerve disorders.

Experts break down the most prevalent falsities ophthalmologists believe about dispensaries, and why believing them are seriously hurting practice revenue.

In her latest blog, Donna Suter gives her advice on creating better communication with your patients.

Guidelines for Case Study Submissions

In her latest blog, Joy Gibb, ABOC, writes how ophthalmologists can fight UPP at the source-your patients.

Patients who are blind from retinitis pigmentosa continue to benefit from a safe retinal implant after 3 years, Ophthalmology reported

In his latest blog, Mark Packer, MD, reflects on ophthalmic pioneers of the past, and writes why controversy and challenging the norm is what drives the future of advancements.

It can be a daunting thought, but due to the ever-growing reliance of the web, do you really know what your patients think of your practice?

Santen recently launched fixed-combination tafluprost and timolol (TAPTIQOM) in the United Kingdom.

Collaborations with practicing ophthalmologists have been crucial to nanotechnology discoveries pertaining to eye diseases, and in which drug can be delivered to the eye.

An age-stratified analysis of endothelial cell count in diabetic and non-diabetic corneas found no statistically significant difference between the groups. Since diabetes may damage the inner layer of the cornea, other variables that affect cell health must also be evaluated.

Forward-looking research in drug delivery and therapies filled the sessions at this year’s meeting of the Association for Research in Vision and Ophthalmology.

Targeting of Myo/Nog cells using a novel nanocarrier complex loaded with doxorubicin is showing promise as a treatment for reducing posterior capsule opacification.

While practice may not always make perfect (at least in this life), it definitely does “make better” not only in sports, but also in the operating room.

Combination treatment with squalamine lactate ophthalmic solution 0.2% and ranibizumab PRN resulted in improved visual function in patients with neovascular age-related macular degeneration compared with treatment with ranibizumab alone.

A novel anti-vascular endothelial growth factor agent, RTH258, produced rapid and sustained improvements in visual acuity and central subfield thickness and was non-inferior to aflibercept in a phase II trial.

New surveillance data on antibiotic resistance among ocular pathogens shows worrisome trends for some widely used drugs while resistance rates for some isolates were relatively stable.